US9849027 — Ocular implantation device
Method of Use · Assigned to Alimera Sciences Inc · Expires 2028-11-07 · 2y remaining
What this patent protects
This patent protects an ocular implantation device with a housing, needle, plunger, and rod that work together to move an implant through the needle.
USPTO Abstract
An ocular implantation device comprises a housing having a longitudinal axis, a needle configured to receive an implant, and a plunger and a rod operatively coupled together. The plunger and the rod are disposed in the housing and are collectively, translationally moveable along the longitudinal axis of the housing. The rod is configured to be receivable within at least a portion of the needle to enable the rod to move the implant therethrough. An actuator is operatively engaged with the plunger such that movement of the actuator in a direction aligned with the longitudinal axis of the housing results in the translational movement of the plunger and the rod along the longitudinal axis of the housing in order to deliver the implant through the needle to a target site. An alternative embodiment of an ocular implantation device uses a retractable needle to deliver an implant.
Drugs covered by this patent
- Derma-Smoothe/Fs (FLUOCINOLONE ACETONIDE) · Eurofarma
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-708 |
— | Derma-Smoothe/Fs |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.